Changes in serum prostate-specific antigen (PSA) can reflect the burden of disease and clinical benefit in patients with castration-resistant prostate cancer (CRPC) with cytotoxic chemotherapy or hormonal agents known to kill tumor cells; these changes can have practical utility by providing and updating prognostic information on an individual patient over time [1-4]. The gene discussed is KLK3; the disease is neoplasm.